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Abstract 
Skeletal, cardiac and smooth muscle cells share various common characteristic features. 
During development the embryonic mesodermal layer contribute at different proportions to the 
formation of these tissues. At the functional level, contractility as well as its decline during 
ageing, are also common features. Cytoskeletal components of these tissues are characterized 
by various actin isoforms that govern through their status (polymerised versus monomeric) and 
their interaction with the myosins the contractile properties of these muscles. Finally, at the 
molecular level, a set of different transcription factors with the notable exception of Serum 
Response Factor SRF- which is commonly enriched in the 3 types of muscle- drive and 
maintain the differentiation of these cells (Myf5, MyoD, Myogenin for skeletal muscle; 
Nkx2.5, GATA4 for cardiomyocytes). In this review, we will focus on the transcription factor 
SRF and its role in the homeostasis of cardiac, smooth and skeletal muscle tissues as well as its 
behaviour during the age related remodelling process of these tissues with a specific emphasis 
on animal models and human data when available. 
Key Words: SRF, Cre/loxP, Muscle tissue, Muscle remodelling, Ageing 
Eur J Transl Myol 2016; 26 (2): 87-92
General features 
SRF, a conserved transcription factor during evolution 
and encoded by a single gene with the exception of 
zebrafish,
1
 is at the confluence of multiple signalling 
pathways controlling the transcription of immediate-
early response genes and muscle-specific genes.
2
 It is a 
member of the MADS box family of transcription 
factors, and binds the core sequence of CArG boxes [CC 
(A/T) 6 GG] as a homodimer
2
. This binding to the core 
CArG box sequence seems to occur in a sequential 
manner as suggested by in vitro biophysical 
experiments.
3
 Despite the low intrinsic transactivating 
capacity, SRF is a potent regulator of gene transcription. 
In vivo and in silico experiments suggest the presence of 
over 200 SRF-regulated target genes.
4
 Indeed, its ability 
to regulate different sets of downstream target genes may 
depend on the promoter context and on its association 
with different cofactors. Among the most studied Srf 
cofactors are the members of the ternary complex factor 
family of Ets domain proteins that are activated by 
MAPK phosphorylation and the family of Myocardin-
related transcriptional co-factors (Myocardin, MrtfA and 
MrtfB).
2,5
 The majority of SRF target genes are involved 
in cell growth, migration, cytoskeletal organization and 
myogenesis. Extensive in vitro studies using fibroblast 
cells by the Treisman lab and others, allowed the 
identification of a robust relationship between SRF and 
actin dynamics. Indeed, Rho family of small GTPases 
that participate in the regulation of actin dynamics 
have been shown to control the nuclear accumulation 
of Srf coactivator Mrtf-A and therefore modulate Srf 
activity.
6,7
 Monomeric G-actin binds to and sequesters 
Srf co-factor Mrtf in the cytoplasm thereby preventing 
Srf activation and gene transcription. Many receptors 
involved in cell/ECM interactions (focal adhesions) or 
cell/cell interface (adherent junctions) have also been 
shown to affect actin dynamics and Mrtf-mediated 
regulation of Srf target genes.
5
 More recently, several 
studies show a major role of SRF in regulating and 
being regulated by various miRNA.
8,9
 
In vivo, the importance of SRF as a crucial 
transcriptional regulator was evidenced by the first 
classical knockout model of this gene reported by 
Nordheim’s lab.10 They showed the requirement of 
SRF in the formation of the mesodermal layer during 
the gastrulation process of embryonic development.  
This early lethal phenotype (E6.5-E8) precluded the 
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possibility to further study the role of SRF in 
organogenesis and in adult mice models. Latter, the 
availability of the Cre/loxP technology allowed our lab 
and others to generate “floxed srf” mice and inactivate 
the gene in an organ and time specific manner.
11-13
 In 
this review we will summarise and comment the results 
obtained upon the inactivation of SRF in the 3 types of 
muscle tissues (skeletal, cardiac and smooth muscle 
cells). 
SRF and the cardiac tissue 
SRF during cardiac development  
Heart development is a complex multiple-stage process 
that requires the coordinated expression of transcription 
factors such as Nkx2.5, GATA4, SRF, MEF2, etc. At 
E8.5 of embryonic development the heart is a linear tube 
that undergoes a rightward looping at stage E9.5. At 
E10.5, the emergence of trabeculations in the luminal 
layers of ventricles enables the myocardium to increase 
its mass. Subsequent septation leads to the formation of a 
four-chambered heart.
14
 In this context, we were first to 
generate cardiac specific knockout of SRF during 
embryonic development using the β-MHC promoter to 
drive Cre expression.
11
 The results obtained showed the 
requirement of SRF for normal cardiac development and 
maturation as evidenced by poor trabeculations, cardiac 
dilatation, and a thin myocardium that were evident at 
stage E11.5, leading to embryonic death.
11
 Two other 
groups using different cardiac specific cre lines found 
similar results.
13,15
 
SRF in the adult heart 
In humans a limited number of studies investigated the 
behaviour of SRF during heart failure and showed the 
presence of dominant negative SRF protein isoforms 
resulting either from the upregulation of a naturally 
occurring SRF RNA isoform or as a result of full length 
SRF cleavage by Caspase-3.
16,17
 In both cases the 
alteration of full-length SRF protein levels could affect 
the expression of key cardiac proteins and thus 
contribute to the failing heart. These results suggest the 
importance of SRF in cardiac homeostasis in adults. 
Consistent with these observations, our mice model of 
tamoxifen inducible cardiac specific SRF knockout led 
to heart failure with dilated cardiomyopathy (DCM).
18
 
This DCM was characterized as in humans by the 
downregulation of energetic proteins such as the muscle 
creatin kinase (MCK) a progressive loss in contractility 
and left ventricular dilation.
18
 Cytoskeletal architecture is 
also altered in these mice as evidenced by the 
enlargement of the intercalated disks, the rapid loss of 
polymerised actin and the gradual loss in the striated 
pattern of desmin.
18,19
 Moreover, Desmin, a preferential 
target of advanced glycation end products (AGE) in 
human DCM showed similar modifications in the SRF 
deficient mouse model.
19
 Taken together, these results 
suggest that SRF could be a key player in the 
remodelling process of human DCM. To our knowledge 
no published data on SRF expression in ageing human 
heart has been reported so far. Data from animal 
models however suggest that SRF protein expression in 
the heart is increased by 20% to 16% in old rats and 
mice as compared to young adult rats as well as its 
binding capacity to target sequences.
20,21
 This 
increased expression could initiate or participate in the 
remodelling process of the ageing cardiac tissue that is 
characterised by a hypertrophic phenotype. Several 
mice models with different levels of SRF 
overexpression suggest such a possibility.
22,23
 Indeed, 
constitutive overexpression of SRF gene in mouse 
heart leads to concentric hypertrophic 
cardiomyopathy.
24
 The requirement of SRF for such a 
hypertrophic response was also evidenced by the 
mosaic deletion of SRF in the cardiac tissue where 
SRF negative cardiomyocytes were unable to undergo 
hypertrophy and showed a thinned phenotype as 
compared to the neighbouring SRF positive 
cardiomyocytes that develop extensive hypertrophy 
upon mechanical stress.
25
 Finally mice models of high 
and low tamoxifen inducible SRF overexpression 
developed in our lab suggest that maintaining an 
adequate level of SRF is crucial for cardiac 
homeostasis. While a low level of SRF overexpression 
(less then 2 fold) did not have any detectable impact on 
cardiac function, a higher then or equal to 4 fold 
overexpression was enough to disturb cardiac 
homeostasis through the alteration of an 
SRF/miRNA133-a/CTGF axis and led to a fibrotic 
cardiac phenotype.
22
 Taken together the limited clinical 
studies and mice models of SRF point to the fact that a 
tight control of SRF expression levels are necessary to 
maintain cardiac homeostasis at different time points in 
life and disruption of its balanced expression could be 
an initiator or a major contributor in the pathological or 
age related cardiac remodelling process. 
SRF and smooth muscle cells 
SRF during vascular smooth muscle development 
During embryonic development vascular smooth 
muscle cells (VSMC) originate mainly from lateral 
mesoderm derived mesenchyme with an additional 
contribution of neural crest cells. They are recruited 
around the primary capillary network to differentiate 
and express characteristic markers such as SM-myosin 
heavy chain, Sm22 and calponin.
26
 However, these 
markers are transiently expressed in cardiac and 
skeletal muscle during embryonic development.
26
 
Despite extensive studies, key tissue restricted 
transcription factors (such as MyoD for skeletal muscle 
or Nkx2.5, GATA4 for cardiac muscle) implicated in 
VSCM differentiation have not been identified 
suggesting the possible absence of such tissue specific 
factors. Studies on DNA regulatory elements and gene 
promoters identified the presence of functional CArG 
boxes and SRF/Myocardin binding as a common 
feature of major VSCM specific genes. A substantial 
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specificity is thus achieved in regulating VSMC 
differentiation. Finally recent evidence suggests a central 
role for epigenetic regulation in SMC differentiation (for 
review see Owens 2014).
27
 Accordingly, inactivation of 
SRF in smooth muscle cells during embryonic 
development using Sm22 promoter to drive Cre 
expression, leads to a decrease in the number of peri-
vascular progenitor cells as well as defects in the cyto-
architecture at E10.5 of development suggesting a 
crucial role for SRF in VSMC differentiation.
13
 The 
other major vascular cell type is the endothelial cell in 
which SRF was also invalidated. Results concerning 
endothelial cells are discussed elsewhere in detail.
28,29
  
SRF in adult smooth muscle cells 
Smooth muscle cells (SMCs) are present at the level of 
visceral organs (intestine, bladder etc.) and the 
vasculature. Viceral SMCs are involved in diverse 
process, including regulation of airway resistance, 
urinary bladder emptying, and gastrointestinal (GI) 
motility. Contractile activity of the smooth muscle layers 
in the gut is crucial for food propulsion and nutrient 
absorption. In this context, inactivation of SRF in 
smooth muscle using the SMC restricted tamoxifen 
inducible Sm22-Cre mice leads to down-regulation of 
many smooth muscle-specific genes in urinary bladder, 
and GI tract. These mice developed a severe form of 
visceral myopathy with a predominant GI failure 
phenotype presenting the features of chronic intestinal 
pseudo-obstruction.
30 
In the vascular system, smooth 
muscle is organised as concentric layers of cells called 
media and surround the layer of endothelial cells. These 
cells are characterised by a contractile activity that is 
essential to maintain a vascular tone.  Smooth muscle 
cells respond to various extracellular signals (the 
autonomic nervous system and various secreted 
molecules) that regulate their contractile status 
(vasoconstriction/ vasodilation) and control blood flow 
and arterial pressure. The contractile and elastic 
properties of vascular smooth muscle cells are altered 
under different pathological conditions and during 
ageing. Indeed these cells have the capacity to reversibly 
modulate their phenotype from a contractile to a 
synthetic proliferative status.31 Two major studies using 
the above-mentioned Cre mice investigated the role of 
SRF in the VSMC either at the level of resistance 
arteries or at the level of large elastic arteries. The first 
study reported an important role of SRF in pressure-
induced myogenic tone in resistance arteries.32 
Resistance arteries paly an important role in the control 
of local blood flow in peripheral tissues. In the absence 
of SRF resistance arteries show a reduced myogenic tone 
(MT) upon increasing pressure by step. This reduced 
myogenic tone is correlated with a decreased sensitivity 
and activity of stretch activated channels (SACs) 
suggesting a role for SRF in maintaining myogenic tone 
in small resistance arteries.32 The second study explored 
the impact of SRF absence on larger arteries (carotid 
and aorta) and more specifically its role in aortic 
stiffness.33 Aortic stiffness is physiologically related to 
ageing and accelerates atheromatosis in the presence of 
other risk factors.  Increasing aortic stiffness with age 
has been mainly attributed to changes in both the 
organization and the content of the extracellular matrix 
(ECM) as well as changes in the structural properties 
of VSMCs. As expected SRF deficient arteries showed 
a decrease in the expression of contractile protein such 
as smooth muscle actin and myosin light chain. Several 
proteins involved in cell-matrix interaction such as 
integrin αV and integrin β3 were also downregulated.33 
These modifications in protein expression were 
suggested to be responsible for the physiological 
alterations observed in mice. Indeed, the absence of 
SRF in VSMCs leads to a reduced arterial stiffness 
suggesting that SRF upregulation during ageing could 
participate in the age related arterial stiffness. Taken 
together these in vivo studies highlight an essential 
regulatory role of SRF in the function and structure of 
elastic and resistance arteries and their remodelling 
during ageing. 
SRF and skeletal muscle 
SRF during skeletal muscle formation and postnatal 
growth  
Skeletal muscle of the limb and trunk derive essentially 
from mesodermal structures called somites and more 
specifically form the dorsal part of these structures. 
Following an initial differentiation step under the 
influence of myogenic determination factors (Myf5, 
MyoD, Myogenin) to form the myotome, these cells 
delaminate and migrate into distant sites such as the 
limb to fuse and form multinucleated muscle fibres.
34,35
 
A potential role for the involvement of SRF in 
myogenesis was first inferred by in vitro experiments 
where the authors showed the requirement of this 
factor for MyoD expression and consequently 
myogenic differentiation and maintenance of muscle 
fibres.
36
 However, subsequent in vivo studies using 
early (Myo-Cre) and late (Mck-Cre) Cre expressing 
lines to delete SRF in myogenic cells failed to block 
MyoD expression, myoblast formation and fusion. 
These mice showed a compromised hypertrophic 
growth necessary for the formation of fully functional 
skeletal muscle and led to early postnatal lethality 
probably due to respiratory failure. These results 
suggest that the Srf mutant phenotype reflects a late 
function of SRF in hypertrophic growth rather than an 
early developmental role.
37
 The use of Cre expressing 
line during early myogenic commitment such as Pax3-
Cre would be of use to rule out or confirm the 
implication of SRF in the early events of myoblast 
formation or fusion. During the postnatal period, 
skeletal muscle achieves its growth by extensive 
synthesis of structural and contractile proteins and the 
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fusion of myogenic stem cells to the existing 
multinucleated muscle fibres. Secreted factors such as 
Igf-1 and Interleukin 4 contribute to the growth of the 
muscle. The role of SRF during this growth phase was 
also investigated in vivo using the human skeletal actin 
promoter to drive Cre recombinase expression. Mutant 
mice displayed growth retardation and a major decrease 
in muscle mass. A sharp decrease in skeletal actin and 
other contractile genes was also evident in these mice. 
Moreover, myofibres lacking SRF displayed a reduced 
myonuclear number and failed to regenerate suggesting a 
possible defect in satellite cell recruitment probably via 
the downregulation of transcription IL-4 and IGF-1 
genes.
38
 
SRF in skeletal muscle homeostasis and ageing 
Under the influence of external or intrinsic cues, adult 
skeletal muscle can change its size, mass and undergo 
reparation following injury-induced damage. This 
plasticity could be compromised in pathological 
conditions such as tumour-induced muscle cachexia or 
defects due to genetic mutations in structural genes such 
as the dystrophin.
39,40
 Ageing also reduces the ability of 
skeletal muscle for reparation and is characterised by 
reduced force generation, sarcopenia and fibrosis.
41,42
 
Several lines of evidence suggest the implication of SRF 
in modulating muscle plasticity. Contrary to the cardiac 
muscle, SRF is downregulated during ageing in human 
and mice skeletal muscle suggesting that this naturally 
occurring decrease in could contribute to the muscle 
phenotype observed during the ageing process and in 
sarcopenia.
43
 Inducing SRF loss in adult myofibers did 
not produce an overt phenotype within the first months 
after triggering SRF disruption suggesting that under 
normal physiological conditions SRF is not implicated in 
muscle homeostasis. However, after several months, 
mutant skeletal muscles develop a wide spectrum of 
alterations including atrophy, fibrosis, lipid 
accumulation and a perturbed regeneration. In 
combination, all these features are characteristic of aged 
skeletal muscle.
43
 Furthermore, the absence of SRF in 
muscle fibres led to altered regenerative response and 
accumulation of fibrosis suggesting a that SRF is 
required for the maintenance of an adequate “niche” for 
the efficient recruitment of muscle satellite cells. The 
defect in satellite cell recruitment in SRF muscle 
deficient mice was further confirmed in a different 
experimental setting where mutant mice failed to 
respond to overload induced hypertrophy and identified 
SRF as a central player in a Il6, Il4, and Cox2 gene 
network.
44
 It could be interesting to further investigate 
the role of SRF in skeletal muscle biology and more 
specifically the role of this factor in muscle stem cells 
using for instance satellite cell specific Cre expressing 
mice (Pax7-Cre). Its role in a pathological setting such as 
cancer-induced muscle cachexia model would also be of 
interest.45 
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